Evaluating the Impact of Fat and Sugar Replacer Blends on Gastrointestinal Tolerance in Biscuits

Inclusion Criteria

• •Non-pregnant, non-lactating, healthy individuals aged 18-55 years, inclusive
• •Body Mass Index (BMI) 18.5-32.0kg/m², inclusive
• •No major illness, trauma or surgery requiring hospitalization within 3 months of the screening visit
• •Ability to understand the study procedures and willing to provide informed consent to participate in the study
• •Non-smokers or smokers who smoke \<10 cigarettes/day and are willing not to change nicotine habits during the study period
• •Willing to limit alcohol consumption to ≤3 standard drinks/day and ≤7 standard drinks/week during the study period
• •Willing to refrain from any marijuana or hemp products during the study period
• •Normal bowel habits (\>2 bowel movements/week and \<3 bowel movements per day)
• •Consumes ≤4 servings/day of fruits and vegetables combined and ≤3 (women) or ≤4 (men) servings/day of whole grains using the definitions of "serving" .
• •Participants must have a cell phone/tablet/computer and be willing and able to use it to collect study data
• •Participants must be eligible to receive income in Canada and be covered by a health insurance plan such as OHIP (Ontario Health Insurance Plan)
• •Participants are willing to follow current COVID guidelines with respect to attending study visits
• •Chronic moderate to severe gastrointestinal symptoms
• •Use of systemic antibiotics, antifungals or antiparasitics in the past 3 months and during the experimental period
• •Use of medications, supplements, and products which may affect the results (laxative, anti-diarrhea, anti-constipation drugs, high fiber supplements)
• •Individuals with any medical conditions or use of supplements or medications that increase risk to the subject or others or may affect the results, as judged by the Principal - Investigator
• •Unwillingness or inability to comply with the experimental procedures and to follow INQUIS safety guidelines
• •Known intolerance, sensitivity, or allergy to any ingredients in the study test products
• •Subject is currently participating or recently (within 30 days of screening) participated in a clinical trial involving long-term exposure (greater than 24 hours) to an investigational drug, nutritional supplement, or lifestyle modification